Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience
Sunshine Biopharma (NASDAQ:SBFM) announced on October 14, 2025 that its Board approved a $5 million strategic investment in Bitcoin (BTC) as a treasury reserve asset.
The Company said the $5 million position will be acquired over time via a regulated digital asset custodian or by buying an ETF or proxy stock, and that it may allocate additional funds to increase Bitcoin holdings in the future. Management framed the move as a hedge and a high-conviction asset to strengthen the company's financial foundation while continuing focus on its drug development pipeline, including antiviral small molecules and mRNA-based cancer therapies.
Sunshine Biopharma (NASDAQ:SBFM) ha comunicato il 14 ottobre 2025 che il suo Consiglio ha approvato un investimento strategico di 5 milioni di dollari in Bitcoin (BTC) come bene di riserva di tesoreria.
L'azienda ha dichiarato che la posizione di 5 milioni di dollari sarà acquistata nel tempo tramite un custode di asset digitali regolamentato o acquistando un ETF o azioni proxy, e che potrebbe destinare ulteriori fondi per aumentare le partecipazioni in Bitcoin in futuro. La direzione ha inquadrato la mossa come una copertura e un asset ad alto grado di convinzione per rafforzare la struttura finanziaria dell'azienda, mantenendo al contempo l'attenzione sul portafoglio di sviluppo di farmaci, inclusi piccoli antivirali e terapie oncologiche basate su mRNA.
Sunshine Biopharma (NASDAQ:SBFM) anunció el 14 de octubre de 2025 que su Junta aprobó una inversión estratégica de 5 millones de dólares en Bitcoin (BTC) como activo de reserva de tesorería.
La compañía indicó que la posición de 5 millones de dólares se adquirirá con el tiempo a través de un custodio regulado de activos digitales o mediante la compra de un ETF o acción proxy, y que podría asignar fondos adicionales para aumentar las participaciones en Bitcoin en el futuro. La dirección enmarcó la medida como una cobertura y un activo de alta convicción para fortalecer los cimientos financieros de la empresa, mientras continúa enfocándose en su canal de desarrollo de medicamentos, incluidos antivirales de moléculas pequeñas y terapias contra el cáncer basadas en ARNm.
Sunshine Biopharma (NASDAQ:SBFM)가 2025년 10월 14일에 이사회가 Bitcoin(BTC)을 보 treasury 자산으로 보유하기 위한 500만 달러의 전략적 투자를 승인했다고 발표했다.
회사는 이 500만 달러 규모의 포지션이 규제된 디지털 자산 관리자를 통해 또는 ETF나 대체 주식을 매입함으로써 시간이 지남에 따라 매입될 것이며, 앞으로도 비트코인 보유를 늘리기 위해 추가 자금을 배정할 수 있다고 밝혔다. 경영진은 이를 헤지 및 고확신 자산으로 간주하여 약물 개발 파이프라인에 집중하는 한편 재무적 기반을 강화하려는 목적이라고 설명했다. 이는 항바이러스 소분자와 mRNA 기반 암 치료제를 포함한다.
Sunshine Biopharma (NASDAQ:SBFM) a annoncé le 14 octobre 2025 que son conseil d'administration a approuvé un investissement stratégique de 5 millions de dollars en Bitcoin (BTC) en tant qu'actif de réserve de trésorerie.
La société a indiqué que la position de 5 millions de dollars serait acquise progressivement via un dépositaire d'actifs numériques réglementé ou en achetant un ETF ou une action proxy, et qu'elle pourrait allouer des fonds supplémentaires pour augmenter ses avoirs en Bitcoin à l'avenir. La direction a présenté cette décision comme une couverture et un actif de forte conviction pour renforcer les bases financières de l'entreprise, tout en poursuivant son focus sur le pipeline de développement de médicaments, y compris les petites molécules antivirales et les thérapies anticancéreuses à base d'ARNm.
Sunshine Biopharma (NASDAQ:SBFM) hat am 14. Oktober 2025 angekündigt, dass sein Vorstand eine strategische Investition von 5 Millionen Dollar in Bitcoin (BTC) als Treasury-Reserven-Asset genehmigt hat.
Das Unternehmen sagte, dass die Position in Höhe von 5 Millionen Dollar im Laufe der Zeit über einen regulierten Custodian für digitale Vermögenswerte oder durch den Kauf eines ETFs oder Proxy-Aktien erworben wird, und dass es in Zukunft weitere Mittel zuweisen könnte, um die Bitcoin-Bestände zu erhöhen. Das Management sah den Schritt als Absicherung und als ein Anlage mit hoher Überzeugung, um die finanzielle Grundlage des Unternehmens zu stärken, während der Fokus weiterhin auf dem Medikamenten-Entwicklungsprogramm liegt, einschließlich antiviraler kleiner Moleküle und mRNA-basierter Krebs Therapien.
Sunshine Biopharma (NASDAQ:SBFM) أعلنت في 14 أكتوبر 2025 أن مجلس إدارتها وافق على استثمار استراتيجي بقيمة 5 ملايين دولار في Bitcoin (BTC) كأصل احتياطي للخزينة.
وقالت الشركة إن موقف 5 ملايين دولار سيُكتسب على مدار الوقت من خلال وكيل أصول رقمية مُنظم أو بشراء صندوق ETF أو أسهم وكيل، وأنها قد تخصّص أموالاً إضافية لزيادة حيازة Bitcoin في المستقبل. أشار الإدارة إلى أن هذه الخطوة تُعد تحوطاً وأصلاً عالي الثقة لتقوية الأسس المالية للشركة مع الاستمرار في التركيز على خط تطوير الأدوية، بما في ذلك جزيئات مضادة للفيروسات صغيرة وت therapies cancer القائمة على الـmRNA.
Sunshine Biopharma (NASDAQ:SBFM) 于 2025年10月14日 宣布，其董事会已批准一项 500万美元 的战略投资，将 Bitcoin (BTC) 作为国债储备资产。
公司表示，这一500万美元的头寸将通过受监管的数字资产托管方逐步取得，或通过购买 ETF 或代理股票来实现，并且未来可能增加资金以提高比特币持有量。管理层将此举定位为对冲手段和高信心资产，旨在加强公司的财务基础，同时继续专注于药物研发管线，包括抗病毒小分子和基于 mRNA 的癌症治疗方案。
- Board-approved $5 million allocation to Bitcoin
- Plan to increase holdings over time as funds become available
- Execution flexibility via custodian, ETF, or proxy stock
- None.
FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals, today announced its Board of Directors has formally approved a strategic investment of
The Company's Bitcoin investment of
"We view Bitcoin not just as a hedge, but as a high-conviction asset with asymmetric upside," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "In an environment of persistent monetary expansion, Bitcoin offers a unique combination of scarcity, liquidity, and global accessibility. It's a natural complement to our long-term capital strategy."
The Company remains fully committed to its core mission of delivering life-saving therapeutics and will continue to focus on its drug development pipeline, including its antiviral small molecules, mRNA-based cancer therapies, and generic drug portfolio.
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 74 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma Inc.
View the original press release on ACCESS Newswire
FAQ
What did Sunshine Biopharma (SBFM) announce on October 14, 2025 about Bitcoin?
How will Sunshine Biopharma (SBFM) buy the $5 million in Bitcoin?
Will Sunshine Biopharma (SBFM) add more to its Bitcoin holdings after the $5 million allocation?
Does the Bitcoin investment change Sunshine Biopharma (SBFM) focus on its drug pipeline?
Why did Sunshine Biopharma (SBFM) choose Bitcoin as a reserve asset?
